These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 31792640)

  • 41. Comparative efficacy and safety of dotinurad, febuxostat, and benzbromarone in hyperuricemic patients with or without gout: A network meta-analysis of randomized controlled trials.
    Lee YH; Song GG
    Int J Clin Pharmacol Ther; 2022 Mar; 60(3):159-166. PubMed ID: 34779393
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ideal pharmacokinetic profile of dotinurad as a selective urate reabsorption inhibitor.
    Omura K; Miyata K; Kobashi S; Ito A; Fushimi M; Uda J; Sasaki T; Iwanaga T; Ohashi T
    Drug Metab Pharmacokinet; 2020 Jun; 35(3):313-320. PubMed ID: 32327267
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of a selective URAT1 inhibitor SHR4640 in Chinese subjects with hyperuricaemia: a randomized controlled phase II study.
    Lin Y; Chen X; Ding H; Ye P; Gu J; Wang X; Jiang Z; Li D; Wang Z; Long W; Li Z; Jiang G; Li X; Bi L; Jiang L; Wu J; Guo L; Cai X; Lu X; Chen Q; Chen H; Peng A; Zuo X; Ning R; Zhang Z; Tai Y; Zhang T; Bao C
    Rheumatology (Oxford); 2021 Nov; 60(11):5089-5097. PubMed ID: 33693494
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Acute kidney injury observed during phase 1 clinical trials of a novel xanthine oxidase/URAT1 dual inhibitor PF-06743649.
    Dua P; Gurrell R; Kirby S; Sudworth M; Loudon PT
    Clin Rheumatol; 2016 Aug; 35(8):2045-2051. PubMed ID: 27094945
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
    Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
    Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dotinurad restores exacerbated kidney dysfunction in hyperuricemic patients with chronic kidney disease.
    Amano H; Kobayashi S; Terawaki H
    BMC Nephrol; 2024 Mar; 25(1):97. PubMed ID: 38491453
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Multicenter, Open-Label Study of Long-Term Topiroxostat (FYX-051) Administration in Japanese Hyperuricemic Patients with or Without Gout.
    Hosoya T; Ishikawa T; Ogawa Y; Sakamoto R; Ohashi T
    Clin Drug Investig; 2018 Dec; 38(12):1135-1143. PubMed ID: 30219951
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout.
    Hosoya T; Ohno I; Nomura S; Hisatome I; Uchida S; Fujimori S; Yamamoto T; Hara S
    Clin Exp Nephrol; 2014 Dec; 18(6):876-84. PubMed ID: 24448692
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-Term Safety and Effectiveness of the Xanthine Oxidoreductase Inhibitor, Topiroxostat in Japanese Hyperuricemic Patients with or Without Gout: A 54-week Open-label, Multicenter, Post-marketing Observational Study.
    Ishikawa T; Maeda T; Hashimoto T; Nakagawa T; Ichikawa K; Sato Y; Kanno Y
    Clin Drug Investig; 2020 Sep; 40(9):847-859. PubMed ID: 32621143
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
    Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Palo WA; Eustace D; Vernillet L; Joseph-Ridge N
    Arthritis Rheum; 2005 Mar; 52(3):916-23. PubMed ID: 15751090
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Efficacy and Safety of Dotinurad on Uric Acid and Renal Function in Patients with Hyperuricemia and Advanced Chronic Kidney Disease: A Single Center, Retrospective Analysis.
    Yanai K; Hirai K; Kaneko S; Mutsuyoshi Y; Kitano T; Miyazawa H; Ito K; Ueda Y; Ookawara S; Morishita Y
    Drug Des Devel Ther; 2023; 17():3233-3248. PubMed ID: 37941891
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S44-9. PubMed ID: 21654269
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney.
    Miner JN; Tan PK; Hyndman D; Liu S; Iverson C; Nanavati P; Hagerty DT; Manhard K; Shen Z; Girardet JL; Yeh LT; Terkeltaub R; Quart B
    Arthritis Res Ther; 2016 Oct; 18(1):214. PubMed ID: 27716403
    [TBL] [Abstract][Full Text] [Related]  

  • 55. GLUT9 influences uric acid concentration in patients with Lesch-Nyhan disease.
    Torres RJ; Puig JG
    Int J Rheum Dis; 2018 Jun; 21(6):1270-1276. PubMed ID: 29879316
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Novel Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Favorable Druggability.
    Zhao T; Meng Q; Sun Z; Chen Y; Ai W; Zhao Z; Kang D; Dong Y; Liang R; Wu T; Pang J; Liu X; Zhan P
    J Med Chem; 2020 Oct; 63(19):10829-10854. PubMed ID: 32897699
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of Febuxostat in Early Gout: A Randomized, Double-Blind, Placebo-Controlled Study.
    Dalbeth N; Saag KG; Palmer WE; Choi HK; Hunt B; MacDonald PA; Thienel U; Gunawardhana L
    Arthritis Rheumatol; 2017 Dec; 69(12):2386-2395. PubMed ID: 28975718
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors.
    Goldfarb DS; MacDonald PA; Hunt B; Gunawardhana L
    J Rheumatol; 2011 Jul; 38(7):1385-9. PubMed ID: 21572152
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Discovery of Flexible Naphthyltriazolylmethane-based Thioacetic Acids as Highly Active Uric Acid Transporter 1 (URAT1) Inhibitors for the Treatment of Hyperuricemia of Gout.
    Zhang X; Wu J; Liu W; Liu Y; Xie Y; Shang Q; Zhou Z; Xu W; Tang L; Wang J; Zhao G
    Med Chem; 2017; 13(3):260-281. PubMed ID: 27633583
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.
    Schumacher HR; Evans RR; Saag KG; Clower J; Jennings W; Weinstein SP; Yancopoulos GD; Wang J; Terkeltaub R
    Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1462-70. PubMed ID: 22549879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.